Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AndroMETa-CRC-560 in refractory metastatic colorectal cancer
CTR20262130Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of telisotuzumab adizutecan, bevacizumab, trifluridine + tipiracil in colorectal cancer (CRC), sponsored by AbbVie Inc.. Started Jun 2026; status: active.
02
Drugs
telisotuzumab adizutecanbevacizumabtrifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20262130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262130.